The primary regulatory authority for health products in Burkina Faso is the Direction Générale de la Pharmacie, du Médicament et des Laboratoires (DGPML), operating under the Ministère de la Santé. The overarching legal framework is anchored in the national pharmaceutical legislation, including the Code de Santé Publique and related ministerial decrees governing the importation, registration, distribution, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly, digital health tools. All health products intended for the Burkinabè market must obtain a Marketing Authorization (Autorisation de Mise sur le Marché, AMM) prior to commercialization, with the DGPML responsible for evaluating dossiers, conducting inspections, and issuing approvals. Burkina Faso is also a member state of the West African Health Organisation (WAHO) and participates in the ECOWAS regional harmonization initiative, which influences its regulatory alignment with neighboring states.
Submission requirements for product registration typically include a complete technical dossier aligned with the Common Technical Document (CTD) format, though adaptations reflecting regional norms and French-language documentation are standard practice. Applicants are generally required to appoint a locally registered legal representative or in-country distributor to act as the regulatory liaison throughout the approval process. Certificates of Pharmaceutical Product (CPP) from the country of manufacture, Good Manufacturing Practice (GMP) compliance evidence, and quality control data are mandatory components of any submission. Burkina Faso has progressively sought to align with ECOWAS and African Union (AU) regulatory harmonization frameworks, including early engagement with the African Medicines Agency (AMA) treaty process. Post-market surveillance obligations, including adverse event reporting and periodic safety updates, are increasingly enforced, though capacity constraints remain a practical challenge within the system.
Public procurement of health products in Burkina Faso is centralized primarily through the Ministère de la Santé, with the Centrale d'Achat des Médicaments Essentiels Génériques et des Consommables Médicaux (CAMEG) serving as the principal national procurement and distribution body for essential medicines, medical supplies, and diagnostic products destined for the public health system. CAMEG operates under government oversight and manages tendering, warehousing, and distribution to regional health districts and public facilities across the country. Large-scale procurement decisions are subject to national public procurement regulations administered by the Direction Générale du Contrôle des Marchés Publics et des Engagements Financiers (DGCMEF), which requires competitive tendering processes, transparency obligations, and compliance with national procurement law. Procurement at the district and facility level is typically guided by standardized essential medicines lists and national treatment guidelines.
Donor-funded and multilateral procurement channels represent a significant portion of health product supply in Burkina Faso, given the country's heavy reliance on external financing for its health system. Key partners include the Global Fund to Fight AIDS, Tuberculosis and Malaria, UNICEF Supply Division, the United States Agency for International Development (USAID) through its implementing mechanisms, and Gavi, the Vaccine Alliance, which supports immunization supply chains. Products procured through these channels may follow the procurement standards of the respective donor organization, including WHO prequalification requirements or Emergency Use Listing (EUL) status, which can create parallel pathways alongside the national AMM process. Local manufacturing capacity in Burkina Faso remains limited, and no robust local manufacturing preference policy is currently in force, though regional policy discussions within ECOWAS increasingly emphasize the importance of building domestic and regional pharmaceutical production capacity in alignment with the AU's Pharmaceutical Manufacturing Plan for Africa.
This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.
Generate a free Market Brief for Burkina Faso →